These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 20102379

  • 1. Changes in cognitive functions of patients with dementia of the Alzheimer type following long-term administration of donepezil hydrochloride: relating to changes attributable to differences in apolipoprotein E phenotype.
    Kanaya K, Abe S, Sakai M, Fujii H, Iwamoto T.
    Geriatr Gerontol Int; 2010 Jan; 10(1):25-31. PubMed ID: 20102379
    [Abstract] [Full Text] [Related]

  • 2. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.
    Wallin AK, Andreasen N, Eriksson S, Båtsman S, Nasman B, Ekdahl A, Kilander L, Grut M, Rydén M, Wallin A, Jonsson M, Olofsson H, Londos E, Wattmo C, Eriksdotter Jonhagen M, Minthon L, Swedish Alzheimer Treatment Study Group.
    Dement Geriatr Cogn Disord; 2007 Jan; 23(3):150-60. PubMed ID: 17312368
    [Abstract] [Full Text] [Related]

  • 3. Effects of donepezil on Alzheimer's disease: the relationship between cognitive function and rapid eye movement sleep.
    Mizuno S, Kameda A, Inagaki T, Horiguchi J.
    Psychiatry Clin Neurosci; 2004 Dec; 58(6):660-5. PubMed ID: 15601392
    [Abstract] [Full Text] [Related]

  • 4. Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting.
    Wattmo C, Hansson O, Wallin AK, Londos E, Minthon L.
    Dement Geriatr Cogn Disord; 2008 Dec; 26(3):203-11. PubMed ID: 18769065
    [Abstract] [Full Text] [Related]

  • 5. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
    Bullock R, Bergman H, Touchon J, Gambina G, He Y, Nagel J, Lane R.
    Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
    Burns A, Gauthier S, Perdomo C.
    Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
    [Abstract] [Full Text] [Related]

  • 7. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E.
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [Abstract] [Full Text] [Related]

  • 8. Impact of donepezil hydrochloride on the care burden of family caregivers of patients with Alzheimer's disease.
    Hashimoto M, Yatabe Y, Kaneda K, Honda K, Ikeda M.
    Psychogeriatrics; 2009 Dec; 9(4):196-203. PubMed ID: 20377821
    [Abstract] [Full Text] [Related]

  • 9. Association between anticholinergic drugs and apolipoprotein E epsilon4 allele and poorer cognitive function in older cardiovascular patients: a cross-sectional study.
    Uusvaara J, Pitkala KH, Tienari PJ, Kautiainen H, Tilvis RS, Strandberg TE.
    J Am Geriatr Soc; 2009 Mar; 57(3):427-31. PubMed ID: 19278396
    [Abstract] [Full Text] [Related]

  • 10. Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis.
    Jelic V, Haglund A, Kowalski J, Langworth S, Winblad B.
    Dement Geriatr Cogn Disord; 2008 Mar; 26(5):458-66. PubMed ID: 18984956
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
    Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM, Donepezil MSAD Study Investigators Group.
    Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
    [Abstract] [Full Text] [Related]

  • 12. Investigation of responders and non-responders to long-term donepezil treatment.
    Inoue J, Hoshino R, Nojima H, Ishida W, Okamoto N.
    Psychogeriatrics; 2010 Jun; 10(2):53-61. PubMed ID: 20738808
    [Abstract] [Full Text] [Related]

  • 13. One-year treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests.
    Borkowska A, Ziolkowska-Kochan M, Rybakowski JK.
    Hum Psychopharmacol; 2005 Aug; 20(6):409-14. PubMed ID: 15991260
    [Abstract] [Full Text] [Related]

  • 14. Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease.
    Tei E, Yamamoto H, Watanabe T, Miyazaki A, Nakadate T, Kato N, Mimura M.
    Growth Horm IGF Res; 2008 Feb; 18(1):47-54. PubMed ID: 17714966
    [Abstract] [Full Text] [Related]

  • 15. Dopamine D3 receptor gene polymorphism influences on behavioral and psychological symptoms of dementia (BPSD) in mild dementia of Alzheimer's type.
    Sato N, Ueki A, Ueno H, Shinjo H, Morita Y.
    J Alzheimers Dis; 2009 Feb; 17(2):441-8. PubMed ID: 19363270
    [Abstract] [Full Text] [Related]

  • 16. Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease.
    Choi SH, Kim SY, Na HR, Kim BK, Yang DW, Kwon JC, Park MY.
    Dement Geriatr Cogn Disord; 2008 Feb; 25(5):445-50. PubMed ID: 18401173
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial.
    Seltzer B, Zolnouni P, Nunez M, Goldman R, Kumar D, Ieni J, Richardson S, Donepezil "402" Study Group.
    Arch Neurol; 2004 Dec; 61(12):1852-6. PubMed ID: 15596605
    [Abstract] [Full Text] [Related]

  • 18. Treatment of behavioral and psychological symptoms of Alzheimer-type dementia with Yokukansan in clinical practice.
    Hayashi Y, Ishida Y, Inoue T, Udagawa M, Takeuchi K, Yoshimuta H, Kiue K, Ninomiya Y, Kawano J, Sameshima T, Kawahara T, Goto I, Shudo K, Kurayama S, Nakamura J, Okahara K, Mitsuyama Y.
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr 16; 34(3):541-5. PubMed ID: 20184936
    [Abstract] [Full Text] [Related]

  • 19. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
    Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, Xu Y, Murthy AK.
    Neurology; 2009 May 05; 72(18):1555-61. PubMed ID: 19176895
    [Abstract] [Full Text] [Related]

  • 20. Cognitive predictors of donepezil therapy response in Alzheimer disease.
    Saumier D, Murtha S, Bergman H, Phillips N, Whitehead V, Chertkow H.
    Dement Geriatr Cogn Disord; 2007 May 05; 24(1):28-35. PubMed ID: 17495473
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.